Breast Cancer Prevention and Control Policy

Objectives

The policy seeks to reduce breast-cancer morbidity and mortality in South Africa and improve quality of life through an integrated control system spanning awareness, prevention, early detection, risk assessment, diagnosis, treatment, survivorship, palliative care, follow-up, surveillance, research and community engagement.[1][2][3]It aims to streamline breast-care services and give all South Africans timely access to a network of breast units and linked services.[1]The framework responds to breast cancer as the most common cancer among South African women and a leading cause of death, while recognising substantial inequalities in access, infrastructure, specialist distribution, referral systems, transport and health-worker capacity.[4][1]

• Improve early recognition through public awareness, education of healthcare workers, prompt assessment of breast symptoms, and resource-appropriate clinical breast examination.[1][5][6]
• Ensure equitable access to timely assessment, triple assessment, diagnosis, staging, treatment, reconstruction, supportive care and palliative care regardless of geographical location or social circumstances.[2][3][7][8]
• Assess breast-cancer risk for eligible women and manage average, moderate and high-risk groups through local protocols, specialist input and genetic services where indicated.[6][9][10]
• Provide risk-adapted screening and specialist care for women known or suspected to carry breast-cancer susceptibility mutations, including BRCA1, BRCA2 and TP53 mutations.[11][12][13]
• Deliver appropriate local and systemic treatment, including surgery, radiotherapy, chemotherapy, biological therapy and hormonal blockade, according to tumour biology, recurrence risk, comorbidities and patient preferences.[14][15][16]
• Support women and families through distress screening, psychological and psychosocial support, breast-care nursing or patient navigation, rehabilitation, lymphoedema care and early palliative care.[17][18][19][20]
• Strengthen monitoring, research and community engagement through facility data, electronic databases, population-based incidence and mortality information, auditing and coordinated information, education and communication.[21][22]

Implementation

Implementation is intended across the public health system at national, provincial and local levels, supported by a programme implementation strategy and clinical guidelines.[23]Care is organised as a tiered, multidisciplinary network linking community services, primary healthcare, district and regional hospitals, specialist breast units, provincial oncology units and, where relevant, private institutions.[24][2][25][26]The National Department of Health leads the policy, with input from clinical experts, the National Health Laboratory Service, civil-society and community-based organisations, technical partners, the Ministerial Advisory Committee for cancers and the Director-General for Health.[23][27]

• Designate and upgrade specialist breast units as centres of excellence for breast-disease management, training, coordination and diagnosis, while provincial oncology units provide definitive medical and radiation oncology services.[25][28]Tailor service configurations to provincial capacity, population density and existing models of care, and refer patients to neighbouring provinces where required services are unavailable.[25][7]
• Train primary healthcare nurses and relevant district clinicians in breast health, clinical breast examination, symptom recognition, triage and referral.[26]Provide opportunistic breast examination and health education in primary care, while urgently referring patients with concerning breast pathology to designated specialist services.[26]
• Establish clear referral pathways, open-access breast clinics, patient navigation, coordinated transport and rapid two-way transfer of clinical information between referring facilities, specialist breast units and oncology units.[25][28][29]Assessment targets include specialist assessment within 21 days for high- or medium-suspicion presentations and within 60 days for low-suspicion presentations.[28]
• Apply triple assessment, comprising clinical examination, imaging and histological confirmation, for eligible patients, supported by image-guided core biopsy, synoptic pathology reporting, receptor testing and laboratory quality-assurance systems.[8][30][31]
• Use multidisciplinary teams to guide diagnosis, treatment, follow-up and care coordination, bringing together relevant surgical, oncology, radiology, pathology, genetics, nursing, psychosocial, rehabilitation and palliative-care expertise.[23][2][13]
• Provide screening selectively rather than introducing population mammography in the public sector, because mammography requires substantial resources and infrastructure.[6]Use clinical breast examination, risk assessment and modality triage to identify women who may benefit from specialist image-based screening.[5][6]
• Integrate breast-cancer prevention and care with chronic-disease prevention, reproductive health, HIV and AIDS services, hepatitis B immunisation, occupational and environmental health, and related national health policies.[24][2]
• Provide ongoing follow-up through clinical review, annual mammography where residual breast tissue remains, symptom-led investigation and avoidance of routine imaging or blood tests for asymptomatic patients.[32][20]
• Collect data from diagnosis throughout the disease course in electronic facility systems, appoint data managers for quality assurance and ethical data use, and maintain breast-unit registries and audit databases.[21][33]Monitor service performance through monthly and annual facility figures, treatment timelines, stage and tumour size at diagnosis, survival by stage, referral and treatment delays, and compliance with unit staffing and functional standards.[28][7][8][21]
• Engage civil-society organisations, non-profit organisations, community health workers, peer counsellors, traditional and religious leaders, and local media in awareness, counselling, myth reduction, support groups and household-level information on screening access.[21][22]

Monitoring & Evaluation

The policy establishes monitoring, evaluation, audit, surveillance and research as core elements of breast cancer control, linking data collection to service quality, timely care, clinical outcomes and system improvement.[1][2][3][21]It combines facility-level monitoring with specialist-unit audits, patient-pathway documentation and national cancer incidence and mortality information.[25][28][21]

• Collect electronic patient information from diagnosis throughout the disease course at all health facilities, supported by a designated data manager responsible for data quality assurance, ethical use of data and responses to audit requests.[21]
• Produce reliable monthly and annual figures from facilities delivering breast examination or care, particularly primary healthcare facilities, specialised breast units and provincial oncology units.[21]
• Maintain breast cancer registries and audit databases in specialised breast units and provincial oncology units, recording referral source, diagnosis, pathology, treatment, outcomes, and intervals from presentation to definitive diagnosis and multidisciplinary-team review.[33]
• Use national population-based cancer-registry and mortality-register information to measure incidence and mortality, with reporting compliance by diagnosing clinicians and pathologists.[21]The policy identifies limitations in the existing pathology-based National Cancer Registry and a lack of population-based data, which contribute to under-reporting of cancer incidence.[1]
• Collect stage and tumour size at diagnosis, survival by stage, and treatment timelines to assess care quality, quantify the public-health burden and inform targeted health-system action.[21]
• Derive key performance indicators from standards of care and conduct continuous audits within and between provinces.[2]Audit designated specialised breast units and provincial oncology units for minimum staffing, functional requirements, service obligations and adherence to national guidelines.[28][33]
• Document individual care pathways through coordinated computerised systems, standardised referral forms, proformas, synoptic pathology reports and multidisciplinary review.[25][28][26][29]

Time-based indicators address access to diagnosis and treatment. The policy seeks treatment initiation within 60 days of first primary healthcare or district-hospital consultation for 90 per cent of high-risk referred women subsequently diagnosed with breast cancer, first definitive treatment within 31 days of the decision to treat, and first adjuvant therapy within 60 to 90 days after surgery.[7]Specialist-unit access standards include assessment within 21 days for high- or medium-suspicion cases and within 60 days for low-suspicion cases.[28]A four-week target applies from first presentation to definitive diagnosis and first multidisciplinary-team visit in the breast-unit standard.[33]

• Monitor uptake of clinical breast examination among eligible women through biannual clinic figures, and use audit and comment forms to identify patient-level and facility-level barriers to uptake.[6]
• Record referrals for genetic assessment, annual genetic-counselling activity, the proportion of patients offered counselling or testing, and annual screening among eligible patients with pathogenic gene mutations.[10][12][13]
• Measure the proportion of patients completing triple assessment, with a target of more than 80 per cent completing it within 21 days.[34]
• Monitor whether at least 90 per cent of patients meet referral timelines for diagnosis and for surgical or non-surgical treatment, while auditing access barriers and delays.[7][8]
• Record multidisciplinary-team decisions on systemic therapy and monitor eligible patients starting neo-adjuvant therapy within 30 days of diagnosis and adjuvant therapy within 90 days of surgery.[16]
• Monitor radiotherapy timeliness, including simulation within 60 days and treatment completion within 120 days; offer radiation within 90 days after breast-conserving surgery and within 60 days after mastectomy for high-burden disease.[35][19]
• Use clinical history and physical examination as the principal post-treatment surveillance approach, with annual mammography where residual breast tissue remains; avoid routine blood tests and diagnostic imaging for asymptomatic patients.[20]

Further monitoring points include emotional-distress screening and appropriate referral, documentation of reconstruction discussions, reconstruction activity, breast-conserving surgery, and axillary lymph-node dissection among node-negative patients.[17][36][14]The supplied material does not set out a single consolidated reporting timetable, national evaluation cycle, enforcement process or comprehensive assignment of accountability beyond data managers, facility audit, multidisciplinary teams and reporting responsibilities for clinicians and pathologists.[21][33]

Costing & Financing

Financing detail is limited. The policy recognises that breast cancer control competes with other health priorities in low- and middle-income settings and requires time and expenditure to establish an effective programme.[24]It links the policy to planned National Health Insurance reform, intended to provide affordable quality services according to health need rather than socioeconomic status.[24]

• Provide a specialised budget for chemotherapy and biological therapies through provincial oncology units or designated points of use.[29][7]
• Support patient navigators through government budgets and engagement with non-governmental organisations.[25]
• Resource specialist breast units, provincial oncology units and referral networks with trained personnel, imaging, pathology and histopathology capacity, tissue-sampling equipment, oncology and surgical infrastructure, computerised records, transport and referral-support systems.[26][29]
• Prioritise clinical breast examination and awareness approaches as simpler and less costly options than population mammography in resource-constrained settings.[5]Mammography requires substantial financial and human resources and should not be introduced for population screening unless resources can effectively and reliably cover at least 70 per cent of women aged 50 years and over.[6]
• Recognise that access to trastuzumab and other HER2-targeted treatments is affected by cost, availability and affordability.[16][37]Pharmaceutical-provider negotiations are identified as a means to avoid treatment expenditure compromising care in other health sectors.[16]
• Develop palliative care, home-care programmes and access to affordable opioids as feasible and cost-effective elements of care in low-resource contexts.[32]
• Implement educational campaigns at low or minimal cost, although no numeric estimate is provided.[22]

No overall programme budget, costed implementation plan, funding allocation, quantified funding gap, financing-source breakdown, resource-mobilisation target or economic model is specified in the supplied material.[2][3][21]The minimum annual caseload of 150 newly diagnosed primary breast cancer cases for a breast unit is described as supporting cost-effective unit functioning, but no associated monetary value is given.[38]